NCT05345002 2026-02-20
All-Trans Retinoic Acid (ATRA) Plus PD-1 Inhibition in Recurrent IDH-Mutant Glioma
Abramson Cancer Center at Penn Medicine
Phase 2 Recruiting
Clinical Trials
6 trialsNCT04919369 2026-02-13
All-Trans Retinoic Acid (ATRA) and Atezolizumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer
Ohio State University Comprehensive Cancer Center
Phase 1 Active not recruiting
NCT06358677 2026-02-13
FACE
University of Utah
Phase 2 Recruiting
NCT07348107 2026-01-16
ATARI-PDAC
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Phase 1 Not yet recruiting
NCT04241276 2026-01-07
STARPAC2
Queen Mary University of London
Phase 2 Active not recruiting
NCT07296445 2025-12-29
LATITUDE
SDK Therapeutics, Inc.
Phase 3 Not yet recruiting